JP2013517283A - 電位依存性ナトリウムチャネル遮断薬 - Google Patents

電位依存性ナトリウムチャネル遮断薬 Download PDF

Info

Publication number
JP2013517283A
JP2013517283A JP2012549074A JP2012549074A JP2013517283A JP 2013517283 A JP2013517283 A JP 2013517283A JP 2012549074 A JP2012549074 A JP 2012549074A JP 2012549074 A JP2012549074 A JP 2012549074A JP 2013517283 A JP2013517283 A JP 2013517283A
Authority
JP
Japan
Prior art keywords
methyl
phenyl
methylethyl
pyridinecarboxylate
piperazinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012549074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517283A5 (enExample
Inventor
ジェフリー、チャールズ、ベーム
ロデリック、エス．デイビス
ジェフリー、ケイ．ケーンズ
リン、クオリャン
ホン、ニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44304640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013517283(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2013517283A publication Critical patent/JP2013517283A/ja
Publication of JP2013517283A5 publication Critical patent/JP2013517283A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012549074A 2010-01-14 2011-01-13 電位依存性ナトリウムチャネル遮断薬 Pending JP2013517283A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29513810P 2010-01-14 2010-01-14
US61/295,138 2010-01-14
US31700510P 2010-03-24 2010-03-24
US61/317,005 2010-03-24
PCT/US2011/021114 WO2011088201A1 (en) 2010-01-14 2011-01-13 Voltage-gated sodium channel blockers

Publications (2)

Publication Number Publication Date
JP2013517283A true JP2013517283A (ja) 2013-05-16
JP2013517283A5 JP2013517283A5 (enExample) 2014-03-13

Family

ID=44304640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012549074A Pending JP2013517283A (ja) 2010-01-14 2011-01-13 電位依存性ナトリウムチャネル遮断薬

Country Status (24)

Country Link
US (1) US20130023541A1 (enExample)
EP (1) EP2523665A4 (enExample)
JP (1) JP2013517283A (enExample)
KR (1) KR20120124064A (enExample)
CN (1) CN102802627A (enExample)
AR (1) AR079906A1 (enExample)
AU (1) AU2011205302B2 (enExample)
BR (1) BR112012017266A2 (enExample)
CA (1) CA2787025A1 (enExample)
CL (1) CL2012001971A1 (enExample)
CO (1) CO6592051A2 (enExample)
CR (1) CR20120402A (enExample)
EA (1) EA201290644A1 (enExample)
IL (1) IL220836A0 (enExample)
MA (1) MA33987B1 (enExample)
MX (1) MX2012008285A (enExample)
NZ (1) NZ601126A (enExample)
PE (1) PE20121518A1 (enExample)
PH (1) PH12012501421A1 (enExample)
SG (1) SG182400A1 (enExample)
TW (1) TW201139406A (enExample)
UY (1) UY33186A (enExample)
WO (1) WO2011088201A1 (enExample)
ZA (1) ZA201205126B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507951A (ja) * 2014-02-27 2017-03-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｎａｖ チャンネル阻害剤としてのヘテロ環化合物及びその使用

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2963028B1 (en) 2009-05-27 2018-08-01 Atir Holding S.A. Piperazine derivatives and their pharmaceutical use
KR101178181B1 (ko) * 2010-09-17 2012-09-19 대한민국(농촌진흥청장) 신규한 항생활성 화합물 및 그 화합물을 포함하는 항생 조성물
WO2012049555A1 (en) 2010-10-13 2012-04-19 Lupin Limited Spirocyclic compounds as voltage-gated sodium channel modulators
EA201490210A1 (ru) * 2011-07-06 2014-05-30 Глэксо Груп Лимитед Блокаторы потенциалзависимых натриевых каналов
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
JP6014155B2 (ja) * 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
AP2014007805A0 (en) 2011-12-28 2014-07-31 Cytokinetics Inc The Regents Of The University Of California Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation
KR101719893B1 (ko) 2012-05-22 2017-03-24 제넨테크, 인크. Ｎ-치환된 벤즈아미드 및 통증의 치료에서 이들의 용도
JP6309519B2 (ja) 2012-07-06 2018-04-11 ジェネンテック， インコーポレイテッド Ｎ置換ベンズアミド及びその使用方法
US9682966B2 (en) * 2012-08-16 2017-06-20 The Scripps Research Institute Kappa opioid ligands
WO2014153037A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
KR20150126620A (ko) 2013-03-14 2015-11-12 다이이찌 산쿄 가부시키가이샤 호흡기 질환용 약
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
PE20151900A1 (es) 2013-03-15 2016-01-20 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ES2909634T3 (es) * 2013-03-15 2022-05-09 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
EP2970156B1 (en) 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
ES2852054T3 (es) 2013-03-15 2021-09-10 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
WO2014165816A1 (en) 2013-04-05 2014-10-09 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
AU2014356967A1 (en) 2013-11-27 2016-07-07 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2015088864A1 (en) * 2013-12-09 2015-06-18 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists
JP6045487B2 (ja) * 2013-12-25 2016-12-14 シャープ株式会社 操作入力システム、電子機器、携帯端末、及び操作入力方法
WO2015120133A1 (en) 2014-02-07 2015-08-13 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TW201623264A (zh) 2014-03-29 2016-07-01 魯賓有限公司 作為電位閘控鈉通道調節劑之磺胺化合物
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
MA42118A (fr) 2015-05-22 2018-03-28 Genentech Inc Benzamides substitués et leurs méthodes d'utilisation
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW201722938A (zh) 2015-09-04 2017-07-01 魯賓有限公司 作為電位閘控鈉通道調節子之磺醯胺化合物
MX386501B (es) 2015-09-28 2025-03-19 Genentech Inc Compuestos terapeuticos y sus metodos de uso
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
SG10201912511WA (en) 2015-12-04 2020-02-27 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
JP2019505508A (ja) 2016-02-03 2019-02-28 シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． 複素環置換ｎ−スルホニルベンズアミド誘導体、その製造方法および医薬における使用
US10766858B2 (en) 2016-03-30 2020-09-08 Genentech, Inc. Substituted benzamides and methods of use thereof
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JP2019532077A (ja) 2016-10-17 2019-11-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
WO2018163077A1 (en) 2017-03-08 2018-09-13 Lupin Limited Indanyl compounds as voltage gated sodium channel modulators
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
CN109796402A (zh) * 2018-12-28 2019-05-24 京博农化科技有限公司 一种烟嘧磺隆中间体2-氯-n，n-二甲基烟酰胺的制备方法
KR102845511B1 (ko) 2019-02-08 2025-08-12 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
EP3936192B1 (en) 2019-03-06 2025-04-09 Daiichi Sankyo Company, Limited Pyrrolopyrazole derivative

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512229A (ja) * 1998-04-20 2002-04-23 ビーエーエスエフ アクチェンゲゼルシャフト カルパインインヒビターとしての複素環式的に置換されたアミド
JP2006522119A (ja) * 2003-03-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド イオンチャネルのモジュレーターとして有用なキナゾリン
JP2007521287A (ja) * 2003-07-02 2007-08-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド 電位依存性イオンチャネルの調節因子として有用なピリミジン
WO2008147864A2 (en) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
JP2009520700A (ja) * 2005-12-21 2009-05-28 ペインセプター ファーマ コーポレーション 依存性イオンチャネルを調節するための組成物および方法
WO2010058060A1 (en) * 2008-11-20 2010-05-27 Orion Corporation Aryl piperazine and their use as alpha2c antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0520581D0 (en) * 2005-10-10 2005-11-16 Glaxo Group Ltd Novel compounds
GB0520578D0 (en) * 2005-10-10 2005-11-16 Glaxo Group Ltd Novel compounds
KR20100007956A (ko) * 2007-05-03 2010-01-22 화이자 리미티드 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512229A (ja) * 1998-04-20 2002-04-23 ビーエーエスエフ アクチェンゲゼルシャフト カルパインインヒビターとしての複素環式的に置換されたアミド
JP2006522119A (ja) * 2003-03-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド イオンチャネルのモジュレーターとして有用なキナゾリン
JP2007521287A (ja) * 2003-07-02 2007-08-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド 電位依存性イオンチャネルの調節因子として有用なピリミジン
JP2009520700A (ja) * 2005-12-21 2009-05-28 ペインセプター ファーマ コーポレーション 依存性イオンチャネルを調節するための組成物および方法
WO2008147864A2 (en) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
WO2010058060A1 (en) * 2008-11-20 2010-05-27 Orion Corporation Aryl piperazine and their use as alpha2c antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6014051107; Ｆａｒｍａｃｉａ　（Ｂｕｃｈａｒｅｓｔ，　Ｒｏｍａｎｉａ） Ｖｏｌ．２５，　Ｎｏ．２, 1977, ｐｐ．７５-８０ *
JPN7014003463; Ｄａｔａｂａｓｅ　ＲＥＧＩＳＴＲＹ , 2007 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507951A (ja) * 2014-02-27 2017-03-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｎａｖ チャンネル阻害剤としてのヘテロ環化合物及びその使用

Also Published As

Publication number Publication date
UY33186A (enExample) 2011-07-29
PE20121518A1 (es) 2012-12-12
BR112012017266A2 (pt) 2016-04-19
AU2011205302A1 (en) 2012-08-02
PH12012501421A1 (en) 2017-08-09
US20130023541A1 (en) 2013-01-24
AU2011205302B2 (en) 2014-10-09
NZ601126A (en) 2014-10-31
CR20120402A (es) 2012-09-03
CO6592051A2 (es) 2013-01-02
CN102802627A (zh) 2012-11-28
EP2523665A1 (en) 2012-11-21
WO2011088201A1 (en) 2011-07-21
KR20120124064A (ko) 2012-11-12
MA33987B1 (fr) 2013-02-01
EP2523665A4 (en) 2013-07-03
TW201139406A (en) 2011-11-16
CL2012001971A1 (es) 2013-01-25
MX2012008285A (es) 2012-08-03
AR079906A1 (es) 2012-02-29
EA201290644A1 (ru) 2012-12-28
ZA201205126B (en) 2013-03-27
IL220836A0 (en) 2012-08-30
SG182400A1 (en) 2012-08-30
CA2787025A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
AU2011205302B2 (en) Voltage-gated sodium channel blockers
US11028071B2 (en) Indazole derivatives as alpha v integrin antagonists
TWI804003B (zh) Tlr7/8拮抗劑及其用途
EP2592933B1 (en) Mif inhibitors and their uses
AU2015223049B2 (en) Heterocyclic compounds as NaV channel inhibitors and uses thereof
US10717736B2 (en) Pyrrole amides as alpha V integrin inhibitors
JP7128811B2 (ja) アルファｖインテグリン阻害剤としてのアゾールアミドおよびアミン
JP2010513458A (ja) Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
TW201819378A (zh) 作為αｖ整合素抑制劑之含環丁烷及氮雜環丁烷之單及螺環化合物
KR20190005838A (ko) 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물
WO2015123408A1 (en) Cyclopropylamines as lsd1 inhibitors
WO2013006596A1 (en) Voltage-gated sodium channel blockers
US7932247B2 (en) M3 muscarinic acetylcholine receptor antagonists
JP2007528420A (ja) 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
JP2023540548A (ja) 抗腫瘍活性を有する化合物及びその使用
EP3009421A1 (en) Glycine transporter inhibitor
TW202430512A (zh) 類木瓜蛋白酶(PLpro)抑制劑
HK1263406B (zh) 作为双重lsd1/hdac抑制剂的环丙基-酰胺化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150602